Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials

Conclusion
OS and rPFS trends demonstrate AA treatment benefit in patients with pre- or post-chemotherapy mCRPC regardless of Gleason score at initial diagnosis. The initial diagnostic Gleason score in patients with mCRPC should not be considered in the decision to treat with AA, as tumour metastases may no longer reflect the histology at the time of diagnosis.

Clinical trials number
COU-AA-301 (NCT00638690); COU-AA-302 (NCT00887198).

Source: Annals of Oncology - March 19, 2016 Category: Cancer & Oncology Authors: Fizazi, K., Flaig, T. W., Stöckle, M., Scher, H. I., de Bono, J. S., Rathkopf, D. E., Ryan, C. J., Kheoh, T., Li, J., Todd, M. B., Griffin, T. W., Molina, A., Ohlmann, C. H. Tags: urogenital tumors Source Type: research